Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06230146
Other study ID # ASUH
Secondary ID
Status Not yet recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date May 1, 2024
Est. completion date May 1, 2026

Study information

Verified date January 2024
Source Assiut University
Contact Doaa Samir, Professor
Phone 01143387171
Email doaasamir1@yahoo.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Keloids are macroscopic cutaneous scarring that result from disturbance of wound healing, that occurs on predisposed individuals . Keloid shows a kind of over-healing, producing over abundant wound matrix responsible for raised, inflexible red scar tissue, that causes pain and itching .


Description:

Multiple hypotheses have been proposed for keloid formation. Though the pathogenesis of keloids is not fully understood, it involves the dysregulation of complex inflammatory pathways . Several studies reported that IGF-IR was overexpressed in keloid fibroblasts . Current treatment options include intralesional and topical therapies, surgical interventions, radiation, and laser-based therapies. Intralesional corticosteroid is the most commonly used nonsurgical treatment for keloids . Fractional laser combined triamcinolone acetonide with may minimize collagen production by decreasing fibroblast activity, with a low recurrence rate of 15.4%, which is superior to each modality. In recent years, physicians were using botulinum toxin A (BTX-A) as a modality for prevention and treatment of keloids. Botulinum toxin type A, isolated from Clostridium botulinum, is a potent neurotoxin that blocks neuromuscular transmission. It has been shown to improve scar cosmesis by decreasing tension on healing wound edges. The role of topical insulin in wound healing has been under search in literature since 1970s . Zhang et al. explored the effect of local insulin injection on systemic blood glucose level and wound healing in patients with diabetic foot ulcer. As far as the investigatorrs are aware, this is the first study to assess the effectiveness and safety of intralesional insulin for the treatment of keloid.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 45
Est. completion date May 1, 2026
Est. primary completion date January 1, 2026
Accepts healthy volunteers No
Gender All
Age group 10 Years and older
Eligibility Inclusion Criteria: - Patients aged equal or more than 10 years old - with keloids diagnosed clinically - with any size less than 10 cm2 Exclusion Criteria: - Pregnancy - Hypertrophic scars - Diabetes mellitus - Kidney or liver disease - Active infection at site of lesion - Lesions suspicious for malignancy - Patients use medications that reduced tissue healing during the study or in a period less than sex months ago (immunosuppressants and isotretinoin) - Patients received any treatment for keloid in the last 3 months

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Insulin group
Fractional ablative laser followed by Intralesional insulin injection (Human actrapid insulin 100 IU\ml solution). Dose: injection of 0.1 ml\cm3 of the lesion avoiding subcutaneous injection as much as possible especially in fatty areas.
Botulinum toxin group
Fractional ablative laser followed by intralesional Botox-A (100 U vacuum-dried powder in a single-use vial for reconstitution diluted in 2 mL of sterile, preservative-free 0.9% saline to constitute a solution at a concentration of 5 U/0.1 mL),It will be injected into the body of the keloid with the help of a 24gauge needle at a distance of 1 cm apart until slight blanching is visible. The dose will be adjusted to 2.5 U/cm3 of the lesion, not exceeding 100 units per session.
Triamcinolone acetonide group
Fractional ablative laser followed by Triamcinolone acetonide injection. TAC 40 mg/ml will be diluted with normal saline solution 0.9% to the concentration of 20 mg/ml .Maximum drug injected during each session will be 40 mg triamcinolone.

Locations

Country Name City State
Egypt Assiut University Assiut

Sponsors (1)

Lead Sponsor Collaborator
Assiut University

Country where clinical trial is conducted

Egypt, 

References & Publications (8)

Betarbet U, Blalock TW. Keloids: A Review of Etiology, Prevention, and Treatment. J Clin Aesthet Dermatol. 2020 Feb;13(2):33-43. Epub 2020 Feb 1. — View Citation

Gassner HG, Sherris DA, Otley CC. Treatment of facial wounds with botulinum toxin A improves cosmetic outcome in primates. Plast Reconstr Surg. 2000 May;105(6):1948-53; discussion 1954-5. doi: 10.1097/00006534-200005000-00005. — View Citation

Ogawa R. Keloid and Hypertrophic Scars Are the Result of Chronic Inflammation in the Reticular Dermis. Int J Mol Sci. 2017 Mar 10;18(3):606. doi: 10.3390/ijms18030606. — View Citation

Ohtsuru A, Yoshimoto H, Ishihara H, Namba H, Yamashita S. Insulin-like growth factor-I (IGF-I)/IGF-I receptor axis and increased invasion activity of fibroblasts in keloid. Endocr J. 2000 Mar;47 Suppl:S41-4. doi: 10.1507/endocrj.47.supplmarch_s41. — View Citation

Thornton NJ, Garcia BA, Hoyer P, Wilkerson MG. Keloid Scars: An Updated Review of Combination Therapies. Cureus. 2021 Jan 30;13(1):e12999. doi: 10.7759/cureus.12999. — View Citation

Walsh LA, Wu E, Pontes D, Kwan KR, Poondru S, Miller CH, Kundu RV. Keloid treatments: an evidence-based systematic review of recent advances. Syst Rev. 2023 Mar 14;12(1):42. doi: 10.1186/s13643-023-02192-7. — View Citation

Wang J, Xu J. Effects of Topical Insulin on Wound Healing: A Review of Animal and Human Evidences. Diabetes Metab Syndr Obes. 2020 Mar 13;13:719-727. doi: 10.2147/DMSO.S237294. eCollection 2020. — View Citation

Zhang Z, Lv L. Effect of local insulin injection on wound vascularization in patients with diabetic foot ulcer. Exp Ther Med. 2016 Feb;11(2):397-402. doi: 10.3892/etm.2015.2917. Epub 2015 Dec 8. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary measure the changes of the level of IGFR1 in keloid before and after different lines of treatment immunohistochemical stain after 6 months of treatment
Secondary measure the changes in size and pliability of keloids after different lines of treatment Vancouver scar scale after 6 months of treatment
See also
  Status Clinical Trial Phase
Recruiting NCT02923596 - Retrospective Study of Keloid Disorder N/A
Completed NCT02922972 - Treatment of Keloid Scar by Autologous Platelet Rich Plasma Obtained With RgenKit-BCT N/A
Terminated NCT01478243 - Study of Psycho-Social Impact of Keloid N/A
Recruiting NCT01423383 - Epidemiology Study of Keloid N/A
Completed NCT03228693 - Gene Expression and Biomarker Profiling of Keloid Skin N/A
Not yet recruiting NCT04326959 - Implantation of Mesenchymal Stem Cell, Conditioned Medium, or Triamcinolone Acetonide for Keloid Phase 1/Phase 2
Recruiting NCT03312166 - Compressive Device to Prevent Keloïd Scars Recurrence [SCARWARS] N/A
Recruiting NCT02823236 - Efficacy of Intralesional Triamcinolone and 8% Topical Pirfenidone for Treatment of Keloid Scars Phase 3
Recruiting NCT04597060 - The Safety and Efficacy of Thermo-mechanical System for Fractional Ablation Associated Triamcinolone Acetonide Drug Delivery for the Treatment of Hypertrophic Scars and Keloids N/A
Completed NCT05939817 - The Effect of Intralesian Injection of Umbilical Cord Mesenchymal Stem Cells, Its Conditioned Medium, and Triamcinolone Acetonide on Type 1:3 Collagen Ratio and Interleukin-10 Levels in Keloid: A Randomised Controlled Trial Phase 4
Completed NCT05887804 - Comparison of Keloid Volume and Symptoms Reduction Between Intralesional Umbilical-Cord Mesenchymal Stem Cells, Its Conditioned Medium, and Triamcinolone Acetonide Injection as Keloid Therapy: A Randomised Controlled Trial Phase 4
Completed NCT03630198 - Pain Outcomes Following Intralesional Corticosteroid Injections Phase 4
Completed NCT04169438 - Pilot Study Investigating a Restorative Wound Care Cream Together With Petrolatum on Surgical Excisions N/A
Recruiting NCT01423981 - Web Based Investigation of Natural History of Keloid Disorder, an Online Survey N/A
Completed NCT01446770 - Evaluation of the Initial Safety and Efficacy of Keloid Lesions Treated With MF-4181 Phase 2
Recruiting NCT06138964 - Comparing the Effect of siSPARC Microneedle Patch Versus siSPARC+siLR4A Microneedle Patch on Post-surgical Scars Phase 3
Enrolling by invitation NCT05461157 - Preoperative Silicone Ointment and Wound Healing N/A
Not yet recruiting NCT04593706 - Comparison of the Efficacy of Different Steroids in the Treatment of Abnormal Scars (Keloids, Hypertrophic Scars) N/A
Active, not recruiting NCT04988022 - Dupilumab in the Treatment of Keloids Phase 4
Withdrawn NCT02546076 - Comparison of Dual-mode ER:YAG Laser in Patients With Long Keloid/Hypertrophic Scars Phase 2